<DOC>
	<DOCNO>NCT00859027</DOCNO>
	<brief_summary>Men treat neoadjuvant luteinizing hormone-releasing hormone ( LHRH ) -agonists leuprolide goserelin prostate cancer become hypogonadal due hormonal suppression demonstrate increase bone turnover consequent bone loss hip spine . This bone loss prevent treatment 35 mg/week risedronate .</brief_summary>
	<brief_title>Effect Of Risedronate On Bone Mass In Older Men Receiving Neoadjuvant Therapy For Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Risedronate Sodium</mesh_term>
	<mesh_term>Etidronic Acid</mesh_term>
	<criteria>Nonmetastatic prostate cancer Men receive Gonadotropinreleasing Hormoneagonist therapy Other cancer except skin cancer Evidence metabolic bone disease Prior use bisphosphonates</criteria>
	<gender>Male</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>Non-metastatic</keyword>
</DOC>